Foreign body reaction after CyPass® Micro-Stent implantation: a case series

Habbe, Kirsten Julia; Kohlhaas, M.; Langwieder, Claus; Fili, Sofia

doi:10.1007/s00417-022-05767-7

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some samples, we noticed FBR cells partially in contact with the islet (Figure 3f). While studies on intraocular implants such as polyimide micro‐stents [ 47 ] transplanted in the supraciliary space and in contact with the aqueous humor have demonstrated fibrosis and other chronic complications, it is suggested that the aqueous humor reinforces fibrotic encapsulation. [ 48 ] Possible direct FBR‐islet interaction needs further assessment.…”

Section: Resultsmentioning

confidence: 99%

3D‐Printed Biohybrid Microstructures Enable Transplantation and Vascularization of Microtissues in the Anterior Chamber of the Eye

Kavand,

Visa,

Köhler

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Hybridizing biological cells with man‐made sensors enable the detection of a wide range of weak physiological responses with high specificity. The anterior chamber of the eye (ACE) is an ideal transplantation site due to its ocular immune privilege and optical transparency, which enable superior noninvasive longitudinal analyses of cells and microtissues. Engraftment of biohybrid microstructures in the ACE may, however, be affected by the pupillary response and dynamics. Here, sutureless transplantation of biohybrid microstructures, 3D printed in IP‐Visio photoresin, containing a precisely localized pancreatic islet to the ACE of mice is presented. The biohybrid microstructures allow mechanical fixation in the ACE, independent of iris dynamics. After transplantation, islets in the microstructures successfully sustain their functionality for over 20 weeks and become vascularized despite physical separation from the vessel source (iris) and immersion in a low‐viscous liquid (aqueous humor) with continuous circulation and clearance. This approach opens new perspectives in biohybrid microtissue transplantation in the ACE, advancing monitoring of microtissue–host interactions, disease modeling, treatment outcomes, and vascularization in engineered tissues.

show abstract

Section: Resultsmentioning

confidence: 99%

3D‐Printed Biohybrid Microstructures Enable Transplantation and Vascularization of Microtissues in the Anterior Chamber of the Eye

Kavand,

Visa,

Köhler

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…However, there is insufficient data on the use of supraciliary shunts in uveitic glaucoma patients. Additionally, there are several reports of granulomatous inflammation or foreign body reaction after CyPass ® implantation, documented histologically after stent explantation, often due to endothelial cell loss [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

XEN®-45 implantation for refractory uveitic glaucoma

Evers,

Anton,

Böhringer

et al. 2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of XEN®-45 gel stent ab interno implantation for medically uncontrolled uveitic glaucoma. Methods Retrospective analysis of 25 eyes receiving XEN® gel stent for medically uncontrolled uveitic glaucoma from February 2019 to February 2023 with recording of intraocular pressure (IOP) values, ocular hypotensive medication, requirement for revision or secondary surgery and complications. Prerequisites for XEN® implantation were a clear cornea, an open iridocorneal angle and an unscarred, mobile conjunctiva at the implantation site. Minimum follow-up required for inclusion was 3 months. The primary outcome measure was IOP compared to baseline. Complete and qualified success were defined as final IOP of ≤ 18 mmHg without or with topical antiglaucomatous treatment, respectively. Failure was defined as IOP > 18 mmHg on two consecutive visits, IOP reduction < 20%, persisting complications from hypotony and open conjunctival bleb revision. Further glaucoma surgical intervention was defined as complete failure. Results Mean preoperative IOP was 35.3 ± 10.9 mmHg on 2.9 ± 0.9 topical antiglaucomatous agents. 19 of 25 patients (76%) received additional oral acetazolamide. 19 eyes were pseudophakic, 5 eyes phakic and 1 aphakic. Early postoperatively, mean IOP reduced to 7.7 ± 3.0 mmHg (75.8% reduction). At final follow-up (mean 17.7 months) mean IOP was 12.0 ± 3.8 mmHg (62.5% reduction) on 0.2 ± 0.6 medications. Six eyes (24%) required bleb revision at mean 28 weeks and therefore were categorized as failure. One eye failed despite bleb revision and restart of topical ocular hypotensive medication. Three other eyes (12%) had IOP spikes with uveitis flare-ups. Transient hypotony complications occurred in 32%. At final follow-up, 18 eyes (72%) achieved complete success and one eye (4%) qualified success. Conclusion The XEN® gel stent effectively reduced IOP in uncontrolled uveitic glaucoma, with 72% complete success. Bleb revision was required in 24%. IOP spikes occurred in 12% despite functioning blebs. Further follow-up is needed to determine long-term outcomes.

show abstract